ReportGem ReportGem

U.S. COMPANY FILING

1Q26 FORM 10-Q

Filed: 2026-05-04Company: Merck & Co., Inc.Ticker: MRKExchange: NYSEForm: 10-QReport period: 2026-03-31SEC accession: 0001628280-26-029802Event: earningsMateriality: 85

Filing text preview

Merck reported a Q1 2026 net loss of $4.24 billion due to a $9.0 billion R&D charge from the Cidara acquisition. Sales rose 5% to $16.3 billion, with Keytruda up 12%. The company agreed to acquire Terns Pharmaceuticals and plans to draw $6.0 billion from a credit facility.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2026-05-04Merck and Moderna's Melanoma Vaccine Trial Positive, Vaccine Themed ETFs Surge2026-08-20S&P 500 and Nasdaq Edge Higher, Led by Moderna and Merck2026-08-2010-Q2026-08-07 · 10-QFORM 8-K2026-08-04 · 8-KFORM 8-K2026-04-30 · 8-K10-K FOR THE FISCAL YEAR ENDED DECEMBER 31, 20252026-02-24 · 10-KFORM 8-K2026-02-03 · 8-K